Pharmaceutical Technology® spoke with Charles Ruban, president and CEO, Verdot, about the focus of moving to sustainability practices in pharmaceutical manufacturing.
The pharmaceutical industry has been moving toward more environmentally friendly practices over the past decade. Regulators have also created sustainability requirements, especially in Europe.
“European regulations are particularly stringent on emissions and product lifecycle sustainability, and they have guided a lot of our initiatives such as a co-design, or carbon offset partnerships,” says Charles Ruban, president and CEO, Verdot.
Both small-molecule and large-molecule drug manufacturing have their own challenges, according to Ruban. Biopharmaceutical manufacturing is energy-intensive and creates material waste during production. Ruban says Verdot approaches the challenges of sustainable biopharmaceutical manufacturing by designing energy-efficient equipment that optimizes the use of material.
“We're partnering with suppliers committed to systemic sustainability, so our carbon-neutral initiative reflects the commitment of overcoming those models while enabling appliances to globally reduce their environmental footprint,” says Ruban.
Click the video above to watch the interview.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.